dacarbazine has been researched along with Adverse Drug Event in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB | 1 |
| Bell, D; Khasraw, M; Wheeler, H | 1 |
| Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G | 1 |
| Boasberg, P; Hamid, O; O'Day, S | 1 |
| Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Kodaira, H; Takeuchi, J; Tanaka, T | 1 |
| Akiyama, T; Goto, T; Hirata, M; Imanishi, J; Kawano, H; Kobayashi, H; Ogura, K; Okuma, T; Shinoda, Y; Tsuda, Y; Yamamoto, A | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Ichihara, A; Naruse, M; Nomura, K; Tanabe, A; Tsuiki, M; Tsumagari, A | 1 |
| Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS | 1 |
| Iwamoto, T | 1 |
| Przybilla, B; Schill, WB | 1 |
4 review(s) available for dacarbazine and Adverse Drug Event
| Article | Year |
|---|---|
Temozolomide-related hematologic toxicity.
Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Hematologic Diseases; Humans; Incidence; Neoplasms; Risk Factors; Temozolomide; Treatment Outcome | 2013 |
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Humans; Ipilimumab; Melanoma; Skin Neoplasms | 2010 |
[Pharmacokinetic and molecular biological approaches to achieve the safety and effective management of drug therapies].
Topics: Anti-Bacterial Agents; Biomarkers; Blood Glucose; Dacarbazine; Diabetes Mellitus; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans; Medication Errors; Nervous System Diseases; Pharmacokinetics; Prednisolone; Risk Factors; Safety Management; Vancomycin | 2007 |
[Side effects of drugs on male fertility].
Topics: Anabolic Agents; Animals; Antifungal Agents; Antineoplastic Agents; Azathioprine; Colchicine; Dacarbazine; Depression, Chemical; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Fertility; Glucocorticoids; Gonadal Steroid Hormones; Histamine H1 Antagonists; Humans; Male; Methotrexate; Retinoids; Sperm Motility; Sperm Transport; Spermatogenesis | 1985 |
3 trial(s) available for dacarbazine and Adverse Drug Event
| Article | Year |
|---|---|
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Temozolomide; Young Adult | 2009 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
9 other study(ies) available for dacarbazine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Time; Treatment Outcome | 2009 |
Successful treatment of Hodgkin lymphoma in second trimester of pregnancy: feasibility of ABVD regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Hodgkin Disease; Humans; Infant, Newborn; Pregnancy; Pregnancy Trimester, Second; Treatment Outcome; Vinblastine | 2011 |
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Sarcoma; Treatment Outcome | 2013 |
Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Vincristine | 2013 |